Clinical Significance of Albuminuria in Patients with Diabetes by 田中 伸枝 et al.
糖尿病患者におけるアルブミン尿の意義












タナ カ ノ ブ エ バ バ ゾ ノ テ ツ ヤ ウチガタ ヤ ス コ
田中 伸枝・馬場園哲也・内潟 安子
（受理 平成 29年 11月 24日）
Clinical Significance of Albuminuria in Patients with Diabetes
Nobue TANAKA, Tetsuya BABAZONO and Yasuko UCHIGATA
Diabetes Center, Tokyo Women’s Medical University School of Medicine
There is a global consensus that early diabetic kidney disease (DKD) is characterized by persistent albumin-
uria. According to international guidelines, albuminuria is defined as a urinary albumin-to-creatinine ratio (ACR)
30 mg/g. Urinary albumin levels should be measured at least once a year. Moreover, albuminuria has been rec-
ognized as a predictor of cardiovascular disease.
In our cohort study including 3,231 diabetic patients, baseline albuminuria, defined as urinary ACR30 mg/
g, was found in 35.1 % of patients; and a decreased estimated glomerular filtration rate (eGFR), defined as eGFR
＜60 mL/min/1.73 m2, was observed in 20.7 % of patients. The hazard ratio (HR) in each group stratified by albu-
minuria and eGFR was analyzed to simultaneously estimate the impact of these renal manifestations on renal out-
comes. Compared to patients with normoalbuminuria and eGFR60 mL/min/1.73 m2, there was no significantly
increased risk for renal endpoints among individuals with normoalbuminuria and eGFR ＜60 mL/min/1.73 m2
[HR: 2.50; 95 % confidence interval (CI) : 0.99-6.33; p = 0.053]. In contrast, those with microalbuminuria and eGFR
60 mL/min/1.73 m2 had a significantly increased risk for renal outcomes (HR: 4.98; 95 % CI: 2.82-8.80; p＜ 0.001).
Therefore, albuminuria may be an independent predictor for the progression of DKD in Japanese patients with
type 2 diabetes. In contrast, the level of eGFR is less likely to be associated with renal endpoints. Further studies
are required to clarify the implications of albuminuria in diabetic patients.
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Table　1　The criteria for the early diagnosis of diabetic nephropathy
1．Subject for assessment
Diabetic patients without proteinuria or with dipstick-positive (＋1) proteinuria
2．Required items
urinary albumin-to-creatinine ratio 30-299 mg/g Cr (2 or more of 3 specimens)
3．Referential items
Urinary albumin excretion rate 30-299 mg/24h or 20-199 μg/min
Type IV collagen more than 7-8 mg/g Cr
Kidney size Renal hypertrophy
The criteria for the early diagnosis of diabetic nephropathy were revised by the Dia-
betic Nephropathy Committee in 2005.





Acute elevation in blood glucose
Acute elevation in blood pressure
Pregnancy
Diabetic patients sometimes have the 
transient albuminuria. Screening of 
albuminuria should be retried in the 




































































dipstick protein test － 658 (91.0 %) 64 (8.9 %) 1 (0.1 %) 723 (100.0 %)
＋/－ 168 (73.0 %)  55 (23.9 %) 7 (3.1 %) 230 (100.0 %)
1＋  36 (31.6 %)  55 (48.2 %) 23 (20.2 %) 114 (100.0 %)
2＋  1 (1.4 %)  18 (25.4 %) 52 (73.2 %)  71 (100.0 %)
3＋  0 (0.0 %)  2 (7.1 %) 26 (92.9 %)  28 (100.0 %)
4＋  0 (0.0 %)  0 (0.0 %)  28 (100.0 %)  28 (100.0 %)




































































クを有する 2型糖尿病患者を対象とした The Ac-
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Table　4　Type 2 diabetic patients stratified by stages of albuminuria and grade of eGFR21)





＞90 (N＝722)   517 (16.0 %) 167 (5.2 %)  38 (1.2 %)
60-89 (N＝1,840) 1,310 (40.5 %)  431 (13.3 %)  99 (3.1 %)
30-59 (N＝590)  264 (8.2 %) 177 (5.5 %) 149 (4.6 %)
15-29 (N＝79)    6 (0.2 %)   6 (0.2 %)  67 (2.1 %)
Data for albuminuria are presented as the number of patients and percentage of total (%).
eGFR, estimated glomerular filtration rate.
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性 1,982名，女性 1,249名，年齢 59±12歳〔平均±








Fig.　1　Hazard ratio of renal outcomes in each group 
stratified by albuminuria and eGFR in type 2 dia-
betic patients
Compared to patients with normoalbuminuria and 
eGFR ＞＿60 mL/min/1.73 m2, there was no signifi-
cantly increased risk for renal endpoints among 
individuals with normoalbuminuria and eGFR ＜60 
mL/min/1.73 m2 [HR: 2.50; 95% confidence interval 
(CI): 0.99-6.33; p＝0.053]. The patients with microal-
buminuria and eGFR ＞＿60 mL/min/1.73 m2 had a 
significantly increased risk for renal outcomes (HR: 


























(ACR < 30 mg/g)
(ACR 30-299 mg/g)









た．eGFR 60 mL/min/1.73 m2以上の正常アルブミン
尿患者に対する eGFR 60 mL/min/1.73 m2未満の正
常アルブミン尿患者におけるハザード比（HR）は
2.50（95％信頼区間［95％CI］0.99-6.33，p=0.053），








行っている２２）．正常アルブミン尿かつ eGFR 60 mL/
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1型糖尿病患者を長期に観察した the Diabetes Con-
trol and Complications Trial/Epidemiology of Dia-
betes Interventions and Complications（DCCT/
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Table　5　Urinary markers associated with diabetic 
kidney disease
Biomarkers of glomerular damage
Type IV collagen33) 34)
Transferrin35) 36)
Micro RNA28) 29)





Liver-type fatty acid binding protein (L-FABP)32)
Neutrophil gelatinase-associated liocalin (NGAL)30) 31)
Kidney injure molecule-1 (KIM-1)30)
There are several markers which consider being associated 
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